Biosimilar Newsletter Archive

1. 06.14.18 -- How Biosimilars Can Win Over U.S. Payers
   6/14/2018
   06/14/18 Biosimilar Development Newsletter
2. 06.07.18 -- Key Learnings Shaping Pfizer’s Biosimilar Business
   6/7/2018
   06/07/18 Biosimilar Development Newsletter
3. 05.31.18 -- The Importance Of Pass-Through Status For Biosimilars
   5/31/2018
   05/31/18 Biosimilar Development Newsletter
4. 05.24.18 -- Incentivizing Clinics: A Biosimilar Maker's Guide
   5/24/2018
   05/24/18 Biosimilar Development Newsletter
5. 05.17.18 -- Pfizer Executives Share Biosimilar Goals, Challenges
   5/17/2018
   05/17/18 Biosimilar Development Newsletter
6. 05.10.18 -- 3 Biosimilar Barriers In Community Clinics
   5/10/2018
   05/10/18 Biosimilar Development Newsletter
7. 05.03.18 -- The Importance Of Humanizing Biosimilars
   5/3/2018
   05/03/18 Biosimilar Development Newsletter
8. 04.26.18 -- 90 Studies Prove Biosimilars’ Safety And Efficacy: What Now?
   4/26/2018
   04/26/18 Biosimilar Development Newsletter
9. 04.19.18 -- Does The U.S. Biosimilar Space Have A Case Of “Progressophobia?”
   4/19/2018
   04/19/18 Biosimilar Development Newsletter
10. 04.12.18 -- Could This Practice Increase U.S. Biosimilar Use?
    4/12/2018
    04/12/18 Biosimilar Development Newsletter